Baotou Tianhe Magnetics Technology
603072
HuangShan Googe
301581
Geovis Insighter Technology
920116
CHICHENG ELECTRIC
834407
Xdc Industries(Shenzhen)Limited
300615
CN Stock MarketDetailed Quotes
688526 Wuhan Keqian Biology Co.,Ltd
- 13.47
- -0.30-2.18%
Market Closed Jan 3 15:00 CST
6.28BMarket Cap20.98P/E (TTM)
14.05High13.43Low19.39KlotVolume13.75Open13.77Pre Close26.55MTurnover0.42%Turnover Ratio15.87P/E (Static)466.13MShares19.7252wk High1.63P/B6.28BFloat Cap11.0052wk Low16.52Limit Up466.13MShs Float50.01Historical High11.02Limit Down4.50%Amplitude11.00Historical Low0.43Dividend TTM13.69Avg Price8.67KlotAsk3.19%Div YieldTTM100Lot Size9.64KlotBid
Wuhan Keqian Biology Co.,Ltd News
Express News | Wuhan Keqian Biology Co.,Ltd: Obtained the veterinary drug GMP certificate and veterinary drug production license.
China Galaxy Securities 2025 Annual Strategy for the Agriculture, Forestry, Animal Husbandry, and Fishery Industry: Focusing on the Breeding Industry Chain, Looking Forward to Efficiency and Growth.
To further boost the growth Sector, investment opportunities in Agriculture in 2025 can still revolve around the breeding Industry Chain.
Wuhan Keqian Biology Co., Ltd (688526.SH): Plans to sign a cooperative research and development agreement with Huazhong Agricultural University.
On December 9th, Gelonghui reported that wuhan keqian biology co.,ltd (688526.SH) announced that in order to enhance the company's market competitiveness and accelerate the development in the biological product industry, thereby better enhancing the company's brand influence and core competitiveness, according to the "Articles of Association," "Cooperative Research and Development Management System," and other regulations, after competitive negotiations with Huazhong Agricultural University, the company has obtained a trivalent inactivated vaccine for chicken infectious rhinitis (Type A + Type B + Type C, recombinant protein), chicken Mycoplasma synoviae, chicken Mycoplasma gallisepticum (HB03 strain + HB15 strain), recombinant Newcastle disease virus, infectious bronchitis virus, and bird flu virus (H9 subtype), and infectious law.
wuhan keqian biology co.,ltd (688526): Revenue improved compared to the previous month, aquaculture warming up, performance expected to grow.
Performance summary: The company released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.666 billion yuan, a year-on-year decrease of -19.57%, and achieved a net income attributable to shareholders of 0.261 billion yuan, a year-on-year decrease of -27.09%; after deducting non-recurring items.
wuhan keqian biology co.,ltd (688526.SH): has repurchased 0.4296% of the shares accumulated.
On November 4th, Keqian Biology (688526.SH) announced that as of October 31, 2024, the company has repurchased a total of 2,002,347 shares through the Shanghai Stock Exchange trading system by means of centralized competitive bidding, accounting for 0.4296% of the total share capital of 466,128,056 shares. The highest repurchase price was 18.90 yuan/share, the lowest price was 13.29 yuan/share, and the total amount paid was RMB 32,945,273.72 yuan (excluding stamp duty, transaction commission, and other transaction costs).
wuhan keqian biology co.,ltd (688526): Profitability improves month-on-month, waiting patiently for the recovery of performance in the later cycle.
Event: In the first three quarters of 2024, the company's revenue decreased by 19.57%, and net income attributable to shareholders decreased by 27.09%. In the first half of 2024, the company achieved revenue of 0.666 billion yuan (a decrease of 19.57% year-on-year) and net income attributable to shareholders of 2.6 billion yuan.
Keqian Biology: Report of Wuhan Keqian Biology Co., Ltd. Third Quarter 2024
Wuhan Keqian Biology Co., Ltd. Report for the Third Quarter of 2024
wuhan keqian biology co.,ltd (688526.SH): net income in the first three quarters was 0.26 billion yuan, a year-on-year decrease of 27.09%.
Gelonghui October 30th | Wuhan Keqian Biology Co.,Ltd (688526.SH) released its third-quarter report, with revenue of 0.666 billion yuan, a 19.57% year-on-year decrease, net income of 0.26 billion yuan, a 27.09% year-on-year decrease, non-GAAP net income of 0.22 billion yuan, a 34.11% year-on-year decrease, and basic EPS of 0.56 yuan.
Express News | Wuhan Keqian Biology Co.,Ltd: The net income in the first three quarters was 0.26 billion yuan, a year-on-year decrease of 27.09%.
Express News | wuhan keqian biology co.,ltd: Obtained a new animal drug registration certificate.
Major shareholder wuhan keqian biology co.,ltd (688526.SH), supervisor Ye Changfa completed the shareholding of 1.8 million shares.
Wuhan Keqian Biology Co.,Ltd (688526.SH) announced that shareholder, supervisor Ye Changfa, holding more than 5% of the shares, conducted block trading...
Wuhan Keqian Biology Co., Ltd. (688526.SH): The actual controller renewed the agreement on acting in concert.
On September 20, Keqian Biology (688526.SH) announced that it has received a notice from Mr. He Qigai, Mr. Wu Bin, Ms. Fang Liurong, and Mr. Wu Meizhou, the actual controllers of the company, regarding the renewal of the "Consolidated Action Agreement". Since the "Consolidated Action Agreement" signed by all parties on September 22, 2023 is about to expire, in order to improve corporate governance, ensure the continuity and stability of the company's operation, and achieve substantial and effective control over the company, all parties have renewed the "Consolidated Action Agreement".
Wuhan Keqian Biology Co., Ltd. (688526.SH): has repurchased 0.4084% of the company's shares.
Keqian Biology (688526.SH) announced that as of August 31, 2024, the company has repurchased 1,903,866 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.4084% of the total share capital of the company, with the highest repurchase price at 18.90 yuan/share and the lowest price at 13.48 yuan/share. The total amount paid was RMB 31,618,428.15 yuan (excluding stamp duty, transaction commission, and other trading expenses).
Wuhan Keqian Biology Co., Ltd. (688526): Short-term pressure on business performance, R&D investment enters the harvest period.
Event: On August 29, 2024, wuhan keqian biology co.,ltd released the 2024 interim report: In 2024H1, the company achieved a revenue of 0.401 billion yuan, a year-on-year decrease of -24.69%, and a net income attributable to the parent company of 0.153 billion yuan, the same.
Wuhan Keqian Biology Co., Ltd. (688526): Waiting for the recovery of the performance in the later stage of the cycle, continuous innovation and R&D growth is expected.
Event: The company's revenue for H1 2024 decreased by 24.69%, and the net income attributable to the parent company decreased by 36.19%. The company achieved revenue of 0.401 billion yuan in the first half of 2024 (a decrease of 24.69% compared to the previous year), and a net income attributable to the parent company of 1.53.
Wuhan Keqian Biology Co., Ltd (Stock Code: 688526) Mid-year Report Review: The company's performance in H1 2024 is under pressure, waiting for the industry demand to recover.
Event: On August 29th, the company released its interim report for 2024. For the first half of 2024, the company achieved revenue/net income attributable to the parent company of 40.1/15.3 billion yuan, a year-on-year decrease of 24.69% and 36.19% respectively. The basic earnings per share (EPS) is 0.33.
Wuhan Keqian Biology Co., Ltd (688526): Intensified competition leads to slower economic recovery, pay attention to the performance of potential new products.
1H24 performance meets our expectations Wuhan Keqian Biology released 1H24 performance: 1H24 revenue YoY -24.7% to 0.401 billion yuan, net profit attributable to parent company/adjusted net profit attributable to parent company YoY -36.2%/-41.6% to 1.
Wuhan Keqian Biology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Wuhan Keqian Biology Co., Ltd.
